Financial Data and Key Metrics Changes - The company presented its annual financial report for the year ending June 30, 2025, but no specific financial data or key metrics were discussed during the meeting [5][6]. Business Line Data and Key Metrics Changes - There were no specific discussions regarding changes in data or key metrics for various business lines during the meeting [6][8]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were mentioned in the meeting [6][8]. Company Strategy and Development Direction and Industry Competition - The meeting focused on formal resolutions and did not provide insights into the company's strategic direction or competitive landscape [5][6]. Management's Comments on Operating Environment and Future Outlook - Management did not provide comments on the operating environment or future outlook during the meeting [6][8]. Other Important Information - The meeting was conducted online, allowing shareholders to participate virtually and submit questions [2][3]. - Voting on resolutions was conducted by poll, with approximately 50.11% of the issued capital represented by proxies [5][6]. Q&A Session Summary Question: Any questions on the financial report? - No questions were raised regarding the financial report [7]. Question: Any questions on the management of the company? - No questions were raised regarding the management of the company [8]. Question: Any questions on the re-election of Dr. Jeremy Levin? - No questions were raised regarding the re-election of Dr. Jeremy Levin [11]. Question: Any questions on the re-election of Ms. Cathy Connell? - No questions were raised regarding the re-election of Ms. Cathy Connell [14]. Question: Any questions on the adoption of the remuneration report? - No questions were raised regarding the adoption of the remuneration report [16]. Question: Any questions on the issue of options to Lawrence Goslin? - No questions were raised regarding the issue of options to Lawrence Goslin [18]. Question: Any questions on the issue of options to Ms. Cathy Connell? - No questions were raised regarding the issue of options to Ms. Cathy Connell [20]. Question: Any questions on the issue of options to Dr. Jeremy Levin? - No questions were raised regarding the issue of options to Dr. Jeremy Levin [23].

Core Insights - Optiva Inc. reported its third quarter financial results for the period ending September 30, 2025, highlighting a strategic transaction with Qvantel aimed at enhancing its position in the BSS market [1][5]. Financial Performance - Revenue for Q3 2025 was $10.1 million, a decrease from $12.0 million in Q3 2024 [6][9]. - Total Contract Value (TCV) bookings for Q3 were $13.4 million, with a trailing twelve-month TCV of $68.8 million [4][5]. - The gross margin for Q3 2025 was 55%, down from 58% in the same period of 2024, primarily due to lower revenue from high-margin services [9]. - Adjusted EBITDA loss for Q3 was $3.9 million, compared to a loss of $0.6 million in Q3 2024 [6][9]. - The net loss for Q3 2025 was $5.7 million, compared to a net loss of $3.4 million in Q3 2024 [6][10]. Strategic Developments - The strategic transaction with Qvantel is expected to close by the end of 2025, creating a combined entity with a competitive portfolio of AI-enabled BSS products [3][5]. - Optiva has secured a contract with a fast-growing MVNO in the APAC region for a full-stack BSS transformation, delivered as a fully managed SaaS solution [5]. - Móvil Éxito, Colombia's first MVNO launched by a retailer, renewed its BSS platform support agreement with Optiva for an additional three years [5]. - A Tier 1 telecom provider in the UK expanded its partnership with Optiva to implement innovative B2B services using Optiva's Application Server [5]. Market Recognition - Optiva was named a finalist for the 2025 Glotel Awards in the category of MVNO Solution of the Year, reflecting its impact in the MVNO/E market [5].

Core Viewpoint - Optiva Inc. is moving forward with a proposed plan of arrangement involving Qvantel Oy, which requires approval from shareholders and noteholders at upcoming meetings [1][2][3] Meeting Details - Special meetings for shareholders and noteholders are scheduled for November 27, 2025, at 10:00 a.m. and 10:30 a.m. Toronto time, respectively [1][2] - Meeting materials have been mailed to shareholders and noteholders of record as of October 27, 2025 [2] Arrangement Resolutions - The Arrangement Resolution requires at least two-thirds (66 ⅔%) approval from shareholders and noteholders, along with a simple majority from minority shareholders [3][6] - Voting results will be announced following the meetings [3] Shareholder and Noteholder Consideration - Shareholders will receive C$0.25 per common share as consideration [7] - Noteholders will receive a combination of voting shares, secured notes totaling US$25 million, warrants, and potential cash payments based on specific conditions [7] Legal Proceedings - An interim order from the Ontario Superior Court of Justice was granted on October 22, 2025, allowing the meetings to proceed [5] - Completion of the arrangement is contingent upon various approvals, including a final order from the court [6] Company Overview - Optiva Inc. specializes in cloud-native, AI-powered revenue management software for the telecommunications industry, established in 1999 and listed on the Toronto Stock Exchange [13]

Core Viewpoint - The strategic transaction between Optiva and Qvantel aims to create a leading global business support system (BSS) provider, enhancing capabilities for communication service providers (CSPs) to drive growth and innovation in the AI era [1][4]. Company Overview - Optiva is recognized for its cloud-native charging and AI-powered BSS solutions, while Qvantel is a leader in digital BSS, together they will offer a comprehensive suite of AI-enabled products [1][3][25][22]. - The combined entity will serve over 70 CSPs across more than 40 countries, leveraging the expertise of over 1,000 professionals [8]. Transaction Details - Qvantel will acquire all issued and outstanding common shares of Optiva, along with US$108.6 million in senior secured PIK toggle notes, through a combination of cash, new notes, shares, and warrants [6][10]. - Shareholders of Optiva will receive $0.25 per share, while noteholders will receive Qvantel shares and additional financial instruments [9][10]. Integration and Future Outlook - The merger is expected to enhance service delivery through a unified global team and a shared corporate culture focused on trust and collaboration [5][4]. - The transaction is anticipated to close in December 2025, with Optiva shares expected to be delisted from the TSX post-transaction [18]. Board Recommendations and Support - The Optiva Board, supported by a special committee, unanimously recommends the transaction, considering it fair and in the best interests of shareholders [12]. - Significant shareholders, representing approximately 67% of Optiva shares, have entered into voting support agreements to favor the transaction [13][15].

Financial Performance - The company incurred total comprehensive losses of US$220.2 million and US$162.8 million for the years ended June 30, 2024 and 2025, respectively, with an accumulated loss of US$742.5 million as of June 30, 2025[52]. - The company has no products approved for commercial sale and has never generated revenue from products, leading to significant financial losses and the expectation of continued losses in the future[52]. - The company has $20 million in cash on hand as of August 20, 2025, which is expected to fund operations into the fourth calendar quarter of 2026[52]. - The company may require additional capital in the future to fund research and development, which may not be available on commercially favorable terms[52]. - Future fundraising efforts may lead to dilution for existing shareholders and could restrict operational capabilities[62]. Strategic Initiatives - Following the DFA Settlement, the company received a cash payment of US$20 million and issued 136,661,003 ordinary shares, equating to 9.99% of the then outstanding issued share capital[41]. - The company is conducting a full strategic review of its business, focusing on the reformulation of its drug candidates and potential clinical trials for other organs[42]. - The company plans to reformulate its drug candidates targeting VEGF-C and/or VEGF-D, with OPT-302 being one of the candidates, to explore various delivery methods[42]. - The company plans to reformulate its portfolio of drug candidates targeting VEGF-C and/or D to treat related disorders following the discontinuation of sozinibercept development[100]. Clinical Development Challenges - The company has faced challenges in enrolling patients for clinical trials and may encounter further difficulties in future trials[46]. - The marketing approval process for future product candidates is expected to be expensive, time-consuming, and uncertain, with no guarantee of commercial success[46]. - The company faces risks related to the lengthy and expensive clinical trial process, which may result in increased costs and delays[67]. - The company has experienced difficulties in patient enrollment for clinical trials, which could further delay development activities[72]. - The company acknowledges a high failure rate for drugs in clinical trials, with many candidates not achieving expected results in later-stage trials[86]. Regulatory and Compliance Risks - Regulatory approval processes are complex and costly, with no guarantee that future product candidates will receive approval[81]. - The company has not received marketing approval for any product candidates to date, and future candidates may not be effective or safe[81]. - The company is subject to various healthcare laws and regulations that could expose it to civil penalties and reputational harm[143]. - The company may face significant additional expenses due to non-tariff costs related to trade between the U.K. and EU post-Brexit[139]. - The company may incur additional compliance costs and face regulatory actions due to the use of generative artificial intelligence technologies in its operations[153]. Market and Competitive Landscape - The company faces substantial competition from large pharmaceutical and biotechnology companies, including Roche, Regeneron, and Novartis, which may impact its market position[90]. - The commercial success of the company's product candidates depends on achieving adequate market acceptance among physicians, patients, and payors[96]. - The company’s projections of addressable patient populations for its product candidates may be overly optimistic, potentially affecting revenue[99]. - The company’s ability to compete effectively is hindered by its limited resources compared to larger competitors, impacting its development and marketing capabilities[92]. Intellectual Property and Legal Risks - The company is pursuing patent applications for its technologies and product candidates, including OPT-302, to protect its intellectual property[197]. - The patent prosecution process is costly and time-consuming, and there is no guarantee that pending applications will result in enforceable patents[200]. - The company may face claims from third parties regarding misappropriation of intellectual property, which could result in litigation and loss of valuable rights[221]. - The company relies on trade secrets and confidentiality agreements to protect its competitive position, but these measures may be inadequate[223]. - A finding of willful infringement could result in significant monetary damages, including treble damages and attorneys' fees, which could hinder the company's ability to commercialize future products[218]. Financial and Market Conditions - Unstable market conditions, including rising inflation and supply chain disruptions, could adversely affect the company's financial condition and growth strategy[66]. - Legislative changes, including the Inflation Reduction Act, may significantly impact drug pricing and reimbursement, affecting the pharmaceutical industry[125]. - The Medicare drug price negotiation program, set to begin in 2026, will negotiate prices for selected drugs, potentially impacting revenue[128]. - State-level regulations are increasingly controlling pharmaceutical pricing, which could harm the company's financial condition and market demand[129]. Manufacturing and Supply Chain Risks - The company relies on third-party manufacturers for production, which introduces risks such as delays in clinical trials and potential compliance issues with regulatory standards[170]. - Manufacturing biologic products is complex and requires significant expertise, with risks including contamination and production yield issues that could affect supply[178]. - The company’s reliance on third-party suppliers may negatively affect profit margins and the ability to commercialize products in a timely manner[176]. - Any adverse developments in manufacturing operations could result in shipment delays, inventory shortages, and potential product recalls[183]. Employee and Management Considerations - Attracting and retaining skilled employees is critical, with intense competition in the biotechnology sector impacting the ability to hire qualified personnel[192]. - The company has streamlined operations and reduced workforce but may increase hiring in the future if new product candidates are identified[192]. - The company is dependent on the expertise of its executive team, and turnover in management could significantly impact its business strategy[193].

Core Viewpoint - Optiva Inc. has entered into an amended support agreement with holders of approximately 85% of its outstanding 9.75% senior secured PIK toggle notes, extending the grace period for negotiations regarding a potential merger transaction until September 30, 2025 [1][2] Group 1: Financial and Transaction Details - The grace period for the 9.75% senior secured PIK toggle notes, originally set to expire on September 3, 2025, has been extended to September 30, 2025 [1] - During this grace period, noteholders have agreed to forbear from exercising their rights related to any payment default on the notes maturing on July 20, 2025 [1] - Optiva is negotiating a potential transaction that may involve exchanging the outstanding principal amount of the notes plus accrued interest for shares and new notes of the combined company [2] Group 2: Shareholder Impact - Common shareholders of Optiva are expected to receive nominal consideration for their shares in connection with the potential transaction [2] - If a definitive agreement is reached within the grace period, the repayment of the notes will be addressed as part of the potential transaction [2] Group 3: Operational Continuity - Despite ongoing negotiations, Optiva plans to continue operating in the ordinary course and uphold commitments to customers, employees, and suppliers [2]

Core Insights - Digitel has renewed its multi-year partnership with Optiva, enhancing its capabilities to innovate and grow in the competitive Venezuelan mobile market [1][2][3] - The renewal allows Digitel to utilize Optiva's full-stack BSS platform, which includes charging, billing, and provisioning, to accelerate product launches and improve customer experiences [1][2] - Digitel currently serves over 7.2 million subscribers and is the first operator to offer 5G technology in Venezuela, leveraging its existing LTE infrastructure for enhanced services [2][4] Company Overview - Digitel is a mobile telephony operator in Venezuela, providing both prepaid and postpaid connectivity solutions tailored for individuals and businesses [4] - The company has a robust 4G LTE network and is expanding its 5G technology in select cities, offering services like VoLTE for high-definition voice calls [4] - Digitel's service portfolio includes international roaming, enterprise solutions, IoT connectivity, and personalized customer support, focusing on quality and efficiency [4] Optiva Overview - Optiva Inc. is a provider of cloud-native, AI-powered revenue management software for the telecommunications sector, helping service providers capitalize on digital and 5G opportunities [5] - Established in 1999 and listed on the Toronto Stock Exchange, Optiva delivers its solutions globally on both private and public cloud platforms [5]

Summary of Opthea Limited (OPT) Corporate Update Webcast Company Overview - **Company**: Opthea Limited (OPT) - **Date of Update**: August 19, 2025 - **Context**: The call discusses the results of phase three clinical trials and the company's future direction following disappointing trial outcomes. Key Points Industry and Clinical Trials - **Phase Three Trials**: The company conducted two pivotal trials, COAST and SHORE, comparing its drug sosinibrocept with existing treatments aflibercept (Eylea) and Lucentis [6][10] - **Primary Endpoint Failure**: Both trials did not meet their primary endpoint of demonstrating superior visual acuity improvement at week 52 compared to the control arms [21][22] - **Patient Population**: Approximately 300 patients were enrolled per arm, with baseline characteristics well balanced across different treatment groups [12][13] - **Results**: The control arm showed a 13.75 letter improvement, while the combination therapy with sosinibrocept did not show statistically significant improvement [14][20] - **Safety Profile**: Sosinibrocept was well tolerated, with similar adverse event rates compared to aflibercept and Lucentis, although there was a slight trend for increased inflammation with higher doses of sosinibrocept [18][22] Financial and Development Funding Agreement (DFA) - **DFA Overview**: In August 2022, the company entered a DFA with OSCELET, initially securing $120 million, later amended to a total of $170 million [24][25] - **Settlement with Investors**: Following negative trial results, the company negotiated a settlement with DFA investors, paying $20 million in cash and providing a 9.99% equity stake, terminating the DFA [27][28] - **Current Cash Position**: As of the update, the company has approximately $20 million in cash on hand and no debt [28][32] Future Strategy and Governance - **Streamlining Operations**: The company has reduced its workforce by over 80% and the board of directors by 50% to align with its current scale [26][33] - **Strategic Review**: A comprehensive strategic review will be undertaken over the next several months to assess internal capabilities and potential partnerships [36][62] - **Focus on Shareholder Return**: The board emphasizes maximizing shareholder return as a primary objective in future decisions [36][64] Additional Insights - **Clinical Trial Insights**: The duration of the trials and patient selection may have impacted outcomes, with suggestions that the phase 2b trial's shorter duration might not have fully informed the phase 3 results [43][44] - **Future Opportunities**: The company is exploring potential therapeutic areas beyond ophthalmology, leveraging its scientific knowledge and assets [48][50] - **R&D Tax Credit**: The company plans to submit for an R&D tax credit, which has not yet been received [55] Conclusion - **Outlook**: The company is positioned to navigate its challenges with a focus on governance, operational efficiency, and strategic partnerships, aiming to enhance shareholder value moving forward [36][39][74]

CORPORATE UPDATE INVESTOR CALL – 20 August 2025 Dr Jeremy Levin – Chairman of the Board Fred Guerard – Chief Executive Officer Tom Reilly – Chief Financial Officer For personal use only Important Information This investor presentation (Presentation) is dated August 19th, 2025 and has been prepared by Opthea Limited (ASX:OTP) (Opthea or the Company). SUMMARY INFORMATION This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offer ...

Core Viewpoint - Opthea Limited has successfully settled the Development Funding Agreement (DFA) with its investors, ensuring the company's solvency and allowing it to continue operations after significant management changes and workforce reductions [1][6][7]. Group 1: DFA Settlement Details - The DFA was terminated following the failure to meet primary endpoints in the COAST and ShORe phase 3 clinical trials, leading to a mutual agreement with the DFA Investors [2][4]. - The settlement includes a one-time cash payment of USD20 million to the DFA Investors and the issuance of equity equivalent to 9.99% of the total issued share capital, amounting to 136,661,003 fully paid ordinary shares [4][6]. - The DFA Investors will enter a voluntary 12-month escrow period for the newly issued shares, with specific exceptions for legal requirements and certain corporate actions [4][5]. Group 2: Management Changes - Dr. Fred Guerard, the outgoing CEO, will step down on September 1, 2025, along with CFO Tom Reilly and Director Sujal Shah, who will leave on September 15, 2025 [1][7]. - Dr. Jeremy Levin will continue as Chairman and take on additional responsibilities as CEO starting September 1, 2025, overseeing the company's strategic direction [1][8]. Group 3: Financial Position and Future Strategy - Following the settlement, Opthea is expected to maintain approximately USD20 million in cash and cash equivalents, ensuring its ability to operate as a going concern [6]. - The company has reduced its workforce by over 80% and cut its Board of Directors by over 50% as part of a strategy to streamline operations [7]. - The Board will focus on maximizing shareholder value and may consider strategic partnerships, internal development, and potential capital returns to shareholders [11].